Cipla Goa facility gets one USFDA observation
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-01-21 06:00 GMT | Update On 2025-01-21 06:00 GMT
Advertisement
Mumbai: Cipla has announced that the United States Food and Drugs Administration (USFDA) has concluded an inspection at the manufacturing facility of Medispray Laboratories Private Limited, a wholly owned subsidiary of the Company located in Kundaim, Goa with one observation.
The facility was inspected from 14th – 20th January, 2025.
"The Company will work closely with the USFDA and remains committed to address these observations comprehensively within stipulated time," Cipla said in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.